Market LIVE
Published markets; coverage varies by country
Product profile · United States

ONFI

 ·  Patent Litigation & Settlement History ↓

IngredientCLOBAZAM
Application typeNDA
Application203993
Product001
Dosage formSUSPENSION
RouteORAL
Strength2.5MG/ML
Approval date2012-12-14
Marketing statusPrescription
Status event—
ApplicantLUNDBECK PHARMS LLC
Product source

Current GenericRadar decision

Year2018
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2018-10-22
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2018-10-22
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
208819 / 001FINAL_APPROVAL · FINAL_APPROVED2018-10-22—BIONPHARMA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209715 / 001FINAL_APPROVAL · FINAL_APPROVED2018-10-22—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210039 / 001FINAL_APPROVAL · FINAL_APPROVED2018-10-22—AMNEAL PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210569 / 001FINAL_APPROVAL · FINAL_APPROVED2018-10-22—UPSHER SMITH LABORATORIES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211259 / 001FINAL_APPROVAL · FINAL_APPROVED2018-10-22—PHARMOBEDIENT CONSULTING LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210546 / 001FINAL_APPROVAL · FINAL_APPROVED2018-12-28—LUPIN LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210978 / 001FINAL_APPROVAL · FINAL_APPROVED2019-04-15—TARO PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210746 / 001FINAL_APPROVAL · FINAL_APPROVED2019-07-10—VISTAPHARM LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211032 / 001FINAL_APPROVAL · FINAL_APPROVED2020-01-31—TEVA PHARMACEUTICALS USANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209796 / 001FINAL_APPROVAL · FINAL_APPROVED2020-02-24—HETERO LABS LTD UNIT IIINEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213110 / 001FINAL_APPROVAL · FINAL_APPROVED2020-04-24—CHARTWELL MOLECULAR HOLDINGS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213039 / 001FINAL_APPROVAL · FINAL_APPROVED2021-05-06—ALKEM LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214404 / 001FINAL_APPROVAL · FINAL_APPROVED2022-03-24—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216008 / 001FINAL_APPROVAL · FINAL_APPROVED2022-09-06—ACCORD HEALTHCARE INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 14 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
208819 / 001BIONPHARMA INCFINAL_APPROVAL · FINAL_APPROVED2018-10-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209715 / 001HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2018-10-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210039 / 001AMNEAL PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2018-10-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210569 / 001UPSHER SMITH LABORATORIES LLCFINAL_APPROVAL · FINAL_APPROVED2018-10-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211259 / 001PHARMOBEDIENT CONSULTING LLCFINAL_APPROVAL · FINAL_APPROVED2018-10-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210546 / 001LUPIN LTDFINAL_APPROVAL · FINAL_APPROVED2018-12-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210978 / 001TARO PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2019-04-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210746 / 001VISTAPHARM LLCFINAL_APPROVAL · FINAL_APPROVED2019-07-10 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211032 / 001TEVA PHARMACEUTICALS USAFINAL_APPROVAL · FINAL_APPROVED2020-01-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209796 / 001HETERO LABS LTD UNIT IIIFINAL_APPROVAL · FINAL_APPROVED2020-02-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213110 / 001CHARTWELL MOLECULAR HOLDINGS LLCFINAL_APPROVAL · FINAL_APPROVED2020-04-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213039 / 001ALKEM LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2021-05-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214404 / 001AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2022-03-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216008 / 001ACCORD HEALTHCARE INCFINAL_APPROVAL · FINAL_APPROVED2022-09-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2018-10-22TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.